- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 9, 2024
Finance
Venture report: Scion’s launch, rounds for Neurona, Attralus and Basking
New firm, affiliated with NYC-based Petrichor, will put $310M fund toward company creation
BioCentury | Feb 24, 2023
Regulation
Feb. 23 Quick Takes: FDA approves Sanofi’s once-weekly hemophilia A therapy
Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more
BioCentury | Mar 10, 2022
Product Development
March 9 Quick Takes: Pfizer and Sobi’s factor VIII therapy meets Phase III endpoints
Plus Adaptive retools, adds CFO, and updates from InxMed, Bayer, Twist-Kriya and more
BioCentury | Feb 22, 2022
Emerging Company Profile
TargED: targeting thrombotic disorders directly at clotting sites
Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications
BioCentury | Feb 1, 2022
Deals
Jan. 31 Quick Takes: After top-line NASH data, Madrigal looks ahead to biopsy readout
Plus Moderna, Novavax, Gandeeva, Cytovation, Takeda
BioCentury | Aug 1, 2020
Emerging Company Profile
VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology
ExeVir emerges with llama-based antibody platform, 1st program for COVID-19
BioCentury | Sep 30, 2019
Company News
Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout
BioCentury | Sep 12, 2019
Distillery Therapeutics
Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers
Items per page:
1 - 10 of 147